SGLT-2i and Cardiovascular Prognosis

Curr Pharm Des. 2020;26(32):3905-3907. doi: 10.2174/138161282632200811172751.

Authors

Gerasimos Siasos¹, Panagiota K Stampouloglou¹, Evanthia Bletsa¹, Stavroula A Paschou¹, Evangelos Oikonomou¹, Georgios Giannopoulos², Spyridon Deftereos², Michael W Cleman², Dimitrios Tousoulis¹

Affiliations

¹ Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, United States.

PMID: 33001001
DOI: 10.2174/138161282632200811172751

No abstract available

Keywords: CVD; SGLT-2i; Type 2 diabetes mellitus; cardiovascular; glucose; heart failure..

MeSH terms

Cardiovascular Diseases* / drug therapy
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Prognosis
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors